ClinicalTrials.gg

Program

etilagimod alpha

Also written as “eftilagimod alpha”, “IMP321” and “IMP321 (eftilagimod alpha)”.

Its studies are mostly in Breast Neoplasms · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Renal Cell, led by 2 companies.

Furthest: phase 3, since Feb 2, 202311 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Immutep S.A.S.101 open or runningphase 3since Feb 2, 2023Jul 7, 2006Jun 2027phase 3 · NCT06726265
Immutep Australia Pty.10 open or runningphase 1since Feb 2, 2016Feb 2, 2016none ahead

Also a collaborator on its studies: Merck and umanis.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 7, 2006First studies: 4 phase 1 studiesNew to Immutep S.A.S.Immutep S.A.S. · NCT00349934, NCT00351949, NCT00354861 and 1 more
  2. Nov 5, 2015Phase 2 study in Adenocarcinoma Breast Stage IVImmutep S.A.S. · NCT02614833 · 242 enrolled · Belgium, France, Germany and more
  3. Feb 2, 2016Immutep Australia Pty.'s first study: phase 1 study in MelanomaNew to Immutep Australia Pty.Immutep Australia Pty. · NCT02676869 · 24 enrolled · Australia
  4. Jul 16, 2018Phase 2 study in Squamous Cell Carcinoma of Head and NeckImmutep S.A.S. · NCT03625323 · 187 enrolled · United States
  5. Jan 29, 2020Phase 1 study in Breast NeoplasmsImmutep S.A.S. · NCT04252768
  6. Mar 19, 2021Phase 2 study in Squamous Cell Carcinoma of Head and NeckImmutep S.A.S. · NCT04811027 · 171 enrolled · United States, Australia, Belgium and more
  7. Feb 2, 2023Phase 3 study in Breast NeoplasmsImmutep S.A.S. · NCT05747794 · 72 enrolled · United States, Belgium, Georgia and more
  8. Dec 3, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungImmutep S.A.S. · NCT06726265 · 756 enrolled · United States, Argentina, Australia and more

Ahead

  1. Jun 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungImmutep S.A.S. · NCT06726265

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06726265Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingImmutep S.A.S.Jun 2027756
NCT05747794Breast Neoplasms · United States, Belgium, Georgia and more3TerminatedImmutep S.A.S.Apr 30, 202672
NCT04811027Squamous Cell Carcinoma of Head and Neck · United States, Australia, Belgium and more2CompletedImmutep S.A.S.Mar 11, 2024171
NCT04252768Breast Neoplasms1WithdrawnImmutep S.A.S.Jun 20250
NCT03625323Squamous Cell Carcinoma of Head and Neck · United States2CompletedImmutep S.A.S.Jun 2, 2022187
NCT02676869Melanoma · Australia1CompletedImmutep Australia Pty.Aug 201924
NCT02614833Adenocarcinoma Breast Stage IV · Belgium, France, Germany and more2CompletedImmutep S.A.S.Mar 2020242
NCT00354861Healthy · France1CompletedImmutep S.A.S.Nov 200548
NCT00354263Healthy · France1CompletedImmutep S.A.S.Sep 200560
NCT00351949Carcinoma, Renal Cell · France1CompletedImmutep S.A.S.Aug 200824
NCT00349934Breast Neoplasms · France1CompletedImmutep S.A.S.Nov 200933

How it is read

Names in the registry

  • “eftilagimod alpha”, 3 entries
  • “IMP321”, 3 entries
  • “IMP321 (eftilagimod alpha)”, 2 entries
  • “eftilagimod alfa”, 1 entry
  • “Eftilagimod Alpha”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.